SPOTLIGHT: Journal posts Velcade data

The British Journal of Haematology has published the results of two phase II studies which showed strong single agent and very high combination response rates in front-line multiple myeloma for Millennium Pharmaceuticals' Velcade. Release

Suggested Articles

The public financing will enable Monopar to start a phase 3 trial of a prophylactic treatment for a side effect of chemoradiotherapy. 

The dispute centers on whether Asa Abeliovich used Alector’s confidential information in connection with his work for Prevail Therapeutics.

GSK poaches Merck KGaA's Martinez-Davis to helm pharma stateside; Bulto named Novartis U.S. pharma head; Allergan's Saunders set for huge parachute.